Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
eIF4A inhibitor
Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from the fruits and twigs of Aglaia foveolata. Silvestrol induces autophagy and caspase-mediated apoptosis. -
eIF2α dephosphorylation inhibitor
Salubrinal is a cell-permeable, selective inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit α (eIF2α). Protects cells from endoplasmic reticulum stress-induced apoptosis (EC50 ~ 15 μM).- Gregory R. Kardos, .et al. , Front Oncol, 2020, 10: 834 PMID: 32637352
-
eIF4A3 inhibitor
eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC50=0.26 μM; Kd=0.043 μM). -
cell cycle inhibitor
Briciclib disodium salt is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. -
PERK inhibitor
ISRIB (mix-isomer) is a potent and selective small molecule inhibitor of PERK signaling (IC50 ~5 nM) that can potently reverse the effects of eIF2α phosphorylation.
-
eIF4E/eIF4G inhibitor
4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 uM.- Amnon Wittenstein, .et al. , PLoS Biol, 2023, Nov 9;21(11):e3002355 PMID: 37943958
-
PERK inhibitor
ISRIB is a potent and selective PERK inhibitor with IC50 of 5 nM.- Le Xu, .et al. , Cell Stem Cell, 2024, Aug 16:S1934-5909(24)00287-X PMID: 39181129
- SeungHye Han, .et al. , Nature, 2023, Aug;620(7975):890-897 PMID: 37558881
- Zhou W, .et al. , Research Square, 2023, MAY 03
- Satoshi Watanabe, .et al. , Proc Natl Acad Sci U S A, 2021, May 18;118(20) PMID: 33972447
- Satoshi Watanabe, .et al. , bioRxiv, 2020, February 27
-
eIF4A3 inhibitor
eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM. -
eIF4G1 inhibitor
SBI-0640756 (SBI-756) is a water soluble inhibitor of eIF4G1 and disrupts the eIF4F complex. -
eIF4A Inhibitor
Zotatifin is a highly selective inhibitor of eIF4A, targeting the assembly of the eIF4F initiation complex. With an IC50 of 2 nM, it promotes eIF4A binding to specific mRNA recognition motifs in the 5’-UTRs. Zotatifin exhibits significant antiviral properties, effectively reducing the infectivity of SARS-CoV-2 by inhibiting the biogenesis of its NP protein (IC90 = 37 nM) and also induces apoptosis in cancer cells. This compound is valuable for studies related to viral infections and translational control mechanisms. -
eIF4G1 Inhibitor
SBI-0640726 is an eIF4G1 inhibitor that exerts antiproliferative effects in melanoma. It disrupts the eIF4F translation initiation complex by targeting the AKT and NF-kB signaling pathways. This compound has demonstrated the ability to inhibit the growth of NRAS and BRAF mutant melanoma cells in vitro, making it a valuable tool for research in cancer biology and therapeutic development. -
eIF4A Inhibitor
rel-Zotatifin is a racemic isomer of Zotatifin, functioning as an inhibitor of the eukaryotic translation initiation factor 4A (eIF4A). This compound exhibits biological activity by promoting eIF4A binding to specific mRNA sequences in the 5’-UTRs, thereby disrupting the assembly of the eIF4F initiation complex. Its key research applications include the study of translation regulation and potential therapeutic interventions in conditions driven by aberrant protein synthesis. -
eIF4A Inhibitor
CR-1-31-B is a synthetic rocaglate that serves as a potent inhibitor of the eukaryotic translation initiation factor eIF4A. By disrupting the interaction between eIF4A and RNA, CR-1-31-B impedes the initiation phase of protein synthesis. This compound has been shown to affect the association of Plasmodium falciparum eIF4A with RNA and induce apoptosis in neuroblastoma and gallbladder cancer cells, making it a valuable tool for studying mechanisms of protein synthesis and cancer biology. -
eIF4A Inhibitor
Didesmethylrocaglamide is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), a key player in the regulation of protein synthesis. This compound demonstrates significant growth-inhibitory activity with an IC50 of 5 nM, effectively suppressing various growth-promoting signaling pathways and inducing apoptosis in tumor cells. Didesmethylrocaglamide is primarily utilized in cancer research to explore its potential therapeutic applications in oncology. -
eIF4A Inhibitor
Rohinitib is a selective inhibitor of eIF4A, a critical protein involved in the regulation of translation initiation. It has demonstrated the ability to induce apoptosis in acute myeloid leukemia (AML) cell lines and effectively reduces leukemia burden in AML xenograft models. Rohinitib is a valuable tool for investigating the mechanisms of AML and exploring potential therapeutic strategies. -
eIF4A Inhibitor
MG-002 is a selective eIF4A inhibitor that interferes with the recruitment and scanning of ribosomes by non-productively trapping the eukaryotic translation initiation factor 4A (eIF4A) onto RNA. This action effectively inhibits mRNA translation, leading to reduced growth and metastasis of triple-negative breast cancer (TNBC) tumors, as well as inducing apoptosis in cancer cells. Additionally, MG-002 significantly downregulates the protein expression of c-MYC and cyclin D1, making it a valuable tool for research applications focused on TNBC and other related malignancies. -
eIF4E Inhibitor
Antiproliferative agent-64 is a potent inhibitor of eukaryotic translation initiation factor 4E (eIF4E), which disrupts the secondary structure of mRNA to effectively inhibit protein translation. This compound exhibits significant biological activity by targeting the 5' untranslated region (5'UTR) of c-Myc with an EC50 of 1.2 nM and the 5'UTR encoding tubulin with an EC50 of 40 nM. Antiproliferative agent-64 also demonstrates considerable antiproliferative effects on MDA-MB-231 cancer cells, with an EC50 of 7 nM, making it a valuable tool for cancer research and the study of translation regulation. -
eIF4A Inhibitor
eIF4A-IN-2 is a potent inhibitor of the eukaryotic translation initiation factor 4A (eIF4A). This compound demonstrates significant cytotoxic activity and can be utilized as a valuable payload in the synthesis of antibody-drug conjugates (ADCs). Researchers investigating translation regulation and therapeutic strategies in cancer may find eIF4A-IN-2 particularly useful for advancing their studies. -
eIF Inhibitor
GCN2-IN-6 is a selective inhibitor of GCN2, exhibiting potent activity with an IC50 of 1.8 nM in enzymatic assays and 9.3 nM in cellular contexts. Additionally, this compound acts as an eIF2α kinase PERK inhibitor, demonstrating an IC50 of 0.26 nM enzymatically and 230 nM in cellular assays. GCN2-IN-6 also features an alkyne functional group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it valuable for biochemical research applications. -
eIF4e Inhibitor
eIF4E-IN-2 is a potent inhibitor targeting eukaryotic initiation factor 4E (eIF4E), with an IC50 of 13 nM. This compound effectively inhibits the proliferation of MDA-MB-361 breast cancer cells, thereby demonstrating its potential in cancer research. eIF4E-IN-2 can be utilized for studies investigating the role of eIF4E in breast cancer progression and therapeutic interventions. -
eIF4A3 Inhibitor
eIF4A3-IN-8 is a selective ATP-competitive inhibitor targeting eukaryotic initiation factor 4A3 (eIF4A3). This compound functions as a valuable chemical probe for investigating the role of eIF4A3 in mRNA processing and the exon junction complex (EJC). Its ability to modulate eIF4A3 activity makes it a useful tool for research into gene expression regulation and related biological pathways. -
eIF4E/eIF4G Interaction Inhibitor
(Z)-4EGI-1 is an inhibitor of the interaction between eIF4E and eIF4G, targeting translation initiation. With an IC50 of 43.5 μM and a Kd value of 8.74 μM, (Z)-4EGI-1 demonstrates significant binding affinity for eIF4E. This compound exhibits anticancer activity, making it a valuable tool for research in cancer biology and studies focused on the regulation of protein synthesis. -
eIF4F Inhibitor
eIF4A3-IN-18 is an effective eIF4F inhibitor that disrupts the assembly of the eIF4F translation complex. It demonstrates potent biological activity with EC50 values of 0.8 nM for myc-LUC, 35 nM for tub-LUC, and inhibits growth in MBA-MB-231 cells. Additionally, eIF4A3-IN-18 exhibits significant cytotoxicity towards RMPI-8226 cells, with an LC50 of 0.06 nM. This compound is valuable for research into the mechanisms of human cancer pathogenesis. -
eIF4F Inhibitor
eIF4A3-IN-12 is an eIF4F inhibitor, specifically disrupting the assembly of the eIF4F translation complex. With EC50 values of 4 nM for myc-LUC, 70 nM for tub-LUC, and 5 nM for inhibiting the growth of MBA-MB-231 cells, this compound demonstrates potent biological activity. eIF4A3-IN-12 is valuable for investigating human cancer pathogenesis and understanding the role of translation regulation in tumorigenesis. -
eIF4F Inhibitor
eIF4A3-IN-16 is a potent eIF4F inhibitor that selectively disrupts the assembly of the eIF4F translation complex. It demonstrates significant biological activity, inhibiting MBA-MB-231 cell growth with an EC50 of 1 nM. Additionally, eIF4A3-IN-16 affects myc-LUC and tub-LUC with EC50 values of 1 nM and 30 nM, respectively. This compound is applicable in research focused on triple negative breast cancer (TNBC). -
eIF4e Inhibitor
eIF4E-IN-3 is a highly effective inhibitor of eukaryotic initiation factor 4E (eIF4E), a critical component in the protein synthesis initiation pathway. This compound demonstrates significant potential in investigating eIF4E-dependent diseases, particularly in cancer research. By modulating eIF4E activity, eIF4E-IN-3 offers valuable insights into the molecular mechanisms underlying tumorigenesis and may aid in the development of targeted therapeutic strategies. -
eIF4F Inhibitor
eIF4A3-IN-15 is a targeted inhibitor of the eIF4F translation complex, effectively disrupting its assembly. This compound demonstrates potent activity with EC50 values of 11, 700, and 120 nM against myc-LUC and tub-LUC, as well as growth inhibition in MBA-MB-231 cancer cells. eIF4A3-IN-15 is suitable for research applications focused on understanding the mechanisms underlying human cancer pathogenesis. -
eIF4F Inhibitor
eIF4A3-IN-9 is a potent eIF4F inhibitor that disrupts the formation of the eIF4F translation complex. Demonstrating EC50 values of 29 nM for myc-LUC, 450 nM for tub-LUC, and an effective growth inhibition in MBA-MB-231 cells, this compound serves as a valuable tool in the study of cancer biology. Its targeted action makes it suitable for investigating human cancer pathogenesis and exploring therapeutic strategies against malignancies. -
eIF Inhibitor
eIF4A3-IN-4 is a selective inhibitor of the eIF4A protein, exhibiting an IC50 value of 8.6 μM. This compound is relevant for research applications targeting the regulation of translation initiation and the modulation of gene expression. It has potential utility in studying cancer biology and other disorders related to abnormal protein synthesis. -
eIF4F Inhibitor
eIF4A3-IN-10 is an inhibitor of the eIF4F translation complex. It exhibits significant biological activity, with EC50 values of 35 nM for myc-LUC and 100 nM for growth inhibition in MBA-MB-231 cancer cells. This compound serves as a valuable tool in researching the pathogenesis of human cancers, particularly in the context of disrupted translation regulation associated with tumorigenesis. -
eIF4F Inhibitor
eIF4A3-IN-17 is an eIF4F inhibitor that disrupts the assembly of the eIF4F translation complex. It has demonstrated potent biological activity with EC50 values of 0.9 nM for myc-LUC, 15 nM for tub-LUC, and 1.8 nM for inhibiting the growth of MBA-MB-231 cells. This compound can be utilized in research focused on understanding human cancer pathogenesis and the mechanisms underlying oncogenic translation regulation. -
eIF4F Inhibitor
eIF4A3-IN-13 is an inhibitor of the eIF4F translation complex, functioning through disruption of its assembly. This compound exhibits potent biological activity, with EC50 values of 0.6 nM for myc-LUC, 15 nM for tub-LUC, and 0.4 nM for growth inhibition in MBA-MB-231 breast cancer cells. eIF4A3-IN-13 is a valuable tool for investigating the mechanisms of human cancer pathogenesis and exploring therapeutic strategies targeting translation regulation. -
eIF4F Inhibitor
eIF4A3-IN-11 is a potent inhibitor of the eIF4F translation complex. It effectively disrupts complex assembly, exhibiting EC50 values of 0.2 nM for myc-Luciferase, 4 nM for tubulin-Luciferase, and 0.3 nM for the inhibition of MBA-MB-231 cancer cell growth. This compound is valuable for investigating the molecular mechanisms underlying human cancer pathogenesis. -
eIF4A Inhibitor
eIF4A3-IN-14 is a selective inhibitor of eIF4A, a crucial component of the eIF4F translation complex. This compound demonstrates potent inhibitory activity with an EC50 of approximately 40 nM against myc-LUC and over 2000 nM against tub-LUC. eIF4A3-IN-14 is valuable for investigating tumorigenesis and the molecular mechanisms of translational regulation in cancer research. -
eIF Inhibitor
CMLD012612 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), designed to disrupt the translation initiation process in eukaryotic cells. This amidino-rocaglate compound features a hydroxamate group, demonstrating significant cytotoxicity in NIH/3T3 cells, with an IC50 value of 2 nM. By modifying the activity of the RNA helicase eIF4A, CMLD012612 exhibits promising anti-neoplastic properties, making it a valuable tool for cancer research and studies focused on translation regulation. -
eIF Inhibitor
CMLD012073 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), functioning through the mechanism of amidino-rocaglates. This compound effectively inhibits cell growth in NIH/3T3 cells with an IC50 value of 10 nM. CMLD012073 disrupts eukaryotic translation initiation by altering the activity of the RNA helicase eIF4A, making it a valuable tool for research applications related to protein synthesis and gene regulation. -
eIF Inhibitor
CMLD012072 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4A1 and eIF4A2 through RNA clamping. This amidino-rocaglate compound exhibits significant anti-neoplastic activity, making it a valuable tool for researching the role of eIF4A in cancer biology and therapeutic interventions. Its mechanism of action provides insight into the regulation of protein synthesis in neoplastic cells, facilitating further studies in oncology and molecular biology. -
eIF4A3 Inhibitor
eIF4A3-IN-7 is a potent inhibitor of the eIF4A3 protein, a key regulator of mRNA translation and splicing. This compound demonstrates significant potential for research in cancer and other dysproliferative diseases by modulating gene expression pathways. Its targeted mechanism of action may provide valuable insights into the role of eIF4A3 in tumorigenesis and other pathological conditions. -
eIF4E Inhibitor
eIF4E-IN-1 is a potent inhibitor of the eIF4E protein, which plays a critical role in regulating protein synthesis and cell proliferation. This compound effectively targets and inhibits immunosuppressive components, including immune checkpoint proteins such as PD-1, PD-L1, LAG3, TIM3, and IDO. eIF4E-IN-1 demonstrates promising biological activity in the modulation of immune responses, making it a valuable tool for research applications in cancer and infectious disease therapies. -
MNK1/MNK2 Inhibitor
HD202A is a selective dual inhibitor of MNK1 and MNK2, exhibiting IC50 values of 6.09 nM and 8.06 nM, respectively. This compound effectively inhibits the MNK-eIF4E signaling pathway, leading to downregulation of perilipin 2 and SCD1, while upregulating adipose triglyceride lipase and PPARγ coactivator 1α. HD202A enhances mitochondrial fatty acid oxidation, redox homeostasis, and demonstrates significant effects on metabolic health, including suppression of body weight gain, reduction in hepatic lipid accumulation, and improvement in glucose tolerance and insulin sensitivity. These properties make HD202A a valuable tool for researching metabolic dysfunction-associated steatotic liver disease. -
eIF4A Inhibitor
eIF4A-IN-1 is a selective inhibitor of eIF4A, a key protein involved in the regulation of mRNA translation. This compound effectively reduces protein synthesis in cancer cells by disrupting the initiation of translation, thereby providing a valuable tool for investigating tumor biology. eIF4A-IN-1 is applicable in studies focused on cancer therapeutics and understanding the mechanisms of tumorigenesis. -
eIF4A Inhibitor
eIF4A3-IN-5 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4AI and eIF4AII. This compound demonstrates significant potential for investigating eIF4A-dependent diseases, particularly in the context of cancer research. Its ability to modulate eIF4A activity makes it a valuable tool for studying mechanisms of protein synthesis and their implications in tumorigenesis. -
eIF4E Inhibitor
eIF4E-IN-4 is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E), demonstrating a biochemical activity value of 95 nM. This compound effectively inhibits cap-dependent mRNA translation, exhibiting an IC50 value of 2.5 μM. eIF4E-IN-4 is valuable for research applications related to breast cancer, colon cancer, and head and neck cancer, providing insights into the role of eIF4E in malignancies. -
eIF4A Inhibitor
eIF4A3-IN-6 is a selective inhibitor of eukaryotic initiation factor 4A (eIF4A), specifically targeting eIF4AI and eIF4AII. This compound exhibits significant biological activity in disrupting eIF4A-mediated processes, making it a valuable tool for studying eIF4A-dependent diseases, particularly in cancer research. The potential applications of eIF4A3-IN-6 extend to elucidating the role of eIF4A in oncogenic mechanisms and therapeutic interventions.
